Expression profile of CD10, Bcl-6, CD138, Bcl-2 and MUM1 and their prognostic value in 136 patients with diffuse large B-cell lymphoma

  • Yan Song
  • Zhi Cao
  • Qin Su
  • Ling Li
  • Hongtu Zhang
  • Yuankai Shi
  • Xun Zhang
Article

Abstract

Objective

We evaluated the value of using a panel of GC B-cell (CD10 and Bcl-6) and activation (MUM1, CD138 and Bcl-2) markers by immunohistochemistry to define prognosis in patients with diffuse large B-cell lymphoma (DLBCL).

Methods

Two different models (Hans’ and modified Chang’s model) were applied on 136 de novo DLBCL patients. Median follow-up in all patients was 39 months (range 5–80 months).

Results

According to Hans’ model, patients with GCB had much better overall survival (5-year OS, 75%) than those with non-GCB (5-year OS, 52%) (Kaplan-Meier survival analysis, P < 0.05, log rank test). According to modified Chang’s model, patients with group 1 had much better overall survival (5-year OS, 78%) than those with group 3 (5-year OS, 44%) while group 2 had no significant value compared with group 1 and group 3 in prognosis (Kaplan-Meier survival analysis, P < 0.05, log-rank test). Using multivariate Cox proportional hazards regression analysis, the international prognostic index scores (IPI), expression of CD138 and the expression pattern of modified Chang’s model were independent prognostic indicators.

Conclusion

Our results suggest that the expression patterns of the panel of GCB-cell and activation markers by immunohistochemistry correlate with prognosis of patients with DLBCL and both models can be used well in ordinary work.

Key words

diffuse large B-cell lymphoma GC B-cell activated B-cell prognosis 

References

  1. 1.
    Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. Lyon: IARC Press, 2001. 127–130.Google Scholar
  2. 2.
    Pileri SA, Dirnhofer S, Went P, et al. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology, 2002, 41: 482–509.CrossRefPubMedGoogle Scholar
  3. 3.
    Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood, 2005, 106: 1164–1174.CrossRefPubMedGoogle Scholar
  4. 4.
    Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med, 1993, 328: 1002–1006.CrossRefPubMedGoogle Scholar
  5. 5.
    Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med, 1995, 333: 1540–1545.CrossRefPubMedGoogle Scholar
  6. 6.
    The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med, 1993, 329: 987–994.CrossRefGoogle Scholar
  7. 7.
    Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000, 403: 503–511.CrossRefPubMedGoogle Scholar
  8. 8.
    Rosenwald A, Wright G, Chan W, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med, 2002, 346: 1937–1947.CrossRefPubMedGoogle Scholar
  9. 9.
    Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004, 103: 275–282.CrossRefPubMedGoogle Scholar
  10. 10.
    Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical Expression Patterns of Germinal Center and Activation B-cell Markers Correlate With Prognosis in Diffuse Large B-cell Lymphoma. Am J Surg Pathol, 2004, 28: 464–470.CrossRefPubMedGoogle Scholar
  11. 11.
    Liu YH, Xu FP, Zhuang HG, et al. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients. Hum Pathol, 2008, 39: 875–884.CrossRefPubMedGoogle Scholar
  12. 12.
    Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: Stein H Swerdlow. Elisa Campo, eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2008. 233–244.Google Scholar
  13. 13.
    Segal MR. Microarray gene expression data with linked survival phenotypes: diffuse large-B-cell lymphoma revisited. Biostatistics, 2006, 7: 268–285.CrossRefPubMedGoogle Scholar
  14. 14.
    Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood, 2002, 99: 1136–1143.CrossRefPubMedGoogle Scholar
  15. 15.
    McClintock S, Perkins SL, Cleveland RP, et al. Immunohistochemical expression pattern of germinal center and activation B-cell markers correlates with prognosis in diffuse large B-cell lymphoma. Mod Pathol, 2003, 16: 244a.Google Scholar
  16. 16.
    Colomo L, López-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood, 2003, 101: 78–84.CrossRefPubMedGoogle Scholar
  17. 17.
    Linderoth J, Jerkeman M, Cavallin-Stahl E, et al. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res, 2003, 9: 722–728.PubMedGoogle Scholar
  18. 18.
    Zinzani PL, Dirnhofer S, Sabattini E, et al. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica, 2005, 90: 341–347.PubMedGoogle Scholar
  19. 19.
    Dogan A, Bagdi E, Munson P, et al. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol, 2000, 24: 846–852.CrossRefPubMedGoogle Scholar
  20. 20.
    Uherova P, Ross CW, Schnitzer B, et al. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma. Am J Clin Pathol, 2001, 115: 582–588.CrossRefPubMedGoogle Scholar
  21. 21.
    Xu Y, McKenna RW, Molberg KH, et al. Clinicopathologic Clinicopathologic analysis of CD10 and bcl-2 diffuse large B-cell lymphoma: identification of a high-risk subset with coexpression of CD10 and Bcl-2. Am J Clin Pathol, 2001, 116: 183–190.CrossRefPubMedGoogle Scholar
  22. 22.
    Chang CC, Cleveland RP, Perkins SL. CD10 expression and survival. Am J Clin Pathol, 2002, 117: 660–661.PubMedGoogle Scholar
  23. 23.
    Zhang A, Ohshima K, Sato K, et al. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas. Pathol Int, 1999, 49: 1043–1052.CrossRefPubMedGoogle Scholar
  24. 24.
    Takeshita M, Iwashita A, Kurihara K, et al. Histologic and immunohistologic findings and prognosis of 40 cases of gastric large B-cell lymphoma. Am J Surg Pathol, 2000, 24: 1641–1649.CrossRefPubMedGoogle Scholar
  25. 25.
    Shiozawa E, Yamochi-Onizuka T, Takimoto M, et al. The GCB subtype of diffuse large B-cell lymphomais less frequent in Asian countries. Leuk Res, 2007, 31: 1579–1583.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Yan Song
    • 1
  • Zhi Cao
    • 1
  • Qin Su
    • 1
  • Ling Li
    • 1
  • Hongtu Zhang
    • 1
  • Yuankai Shi
    • 2
  • Xun Zhang
    • 1
  1. 1.Department of Pathology, Cancer Institute and HospitalChinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC)BeijingChina
  2. 2.Department of Medical Oncology, Cancer Institute and HospitalChinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC)BeijingChina

Personalised recommendations